Contineum Therapeutics, Inc. Earnings Per Share (Basic)
Contineum Therapeutics, Inc. (CTNM) reported Earnings Per Share (Basic) of -$0.40 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-07-30
- Contineum Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.40.
- Contineum Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.39.
- Contineum Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.45.
- Contineum Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-06-30 was -$0.62.
- Contineum Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$2.17.
- Contineum Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$2.18, a 260.29% decline from fiscal 2023.
- Contineum Therapeutics, Inc. earnings per share, basic for fiscal 2023 was $1.36.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.40 10-Q · filed 2026-07-30 | -$0.79 10-Q · filed 2026-07-30 | ||
| 2026-03-31 | -$0.39 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | -$2.17 10-K · filed 2026-03-05 | |||
| 2025-09-30 | -$0.45 10-Q · filed 2025-10-30 | -$1.07 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$1.68 10-Q · filed 2025-10-30 | -$2.25 derived: net income ÷ weighted average shares · filed 2026-07-30 |
| 2025-06-30 | -$0.62 10-Q · filed 2026-07-30 | -$1.24 10-Q · filed 2026-07-30 | -$1.80 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$2.20 derived: net income ÷ weighted average shares · filed 2026-07-30 |
| 2025-03-31 | -$0.62 10-Q · filed 2026-05-05 | -$1.18 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$1.58 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$1.98 derived: net income ÷ weighted average shares · filed 2026-05-05 |
| 2024-12-31 | -$0.56 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$0.96 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$1.35 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$2.18 10-K · filed 2026-03-05 |
| 2024-09-30 | -$0.40 10-Q · filed 2025-10-30 | -$0.79 derived: net income ÷ weighted average shares · filed 2025-10-30 | -$1.61 10-Q · filed 2025-10-30 | -$2.15 derived: net income ÷ weighted average shares · filed 2025-10-30 |
| 2024-06-30 | -$0.39 10-Q · filed 2025-08-05 | -$1.35 10-Q · filed 2025-08-05 | -$1.99 derived: net income ÷ weighted average shares · filed 2025-08-05 | -$3.27 derived: net income ÷ weighted average shares · filed 2025-08-05 |
| 2024-03-31 | -$3.55 10-Q · filed 2025-05-14 | -$4.08 derived: net income ÷ weighted average shares · filed 2025-05-14 | -$6.76 derived: net income ÷ weighted average shares · filed 2025-05-14 | -$4.29 derived: net income ÷ weighted average shares · filed 2025-05-14 |
| 2023-12-31 | -$0.51 derived: net income ÷ weighted average shares · filed 2025-03-06 | -$3.19 derived: net income ÷ weighted average shares · filed 2025-03-06 | -$0.68 derived: net income ÷ weighted average shares · filed 2025-03-06 | $1.36 10-K · filed 2025-03-06 |
| 2023-09-30 | -$2.69 10-Q · filed 2024-11-06 | -$0.17 derived: net income ÷ weighted average shares · filed 2024-11-06 | $1.89 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $2.56 10-Q · filed 2024-08-14 | $2.42 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$2.12 10-Q · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |